MedWatch

Bank says not to expect surprises in Demant's Q1 report

France’s healthcare reform makes for a difficult basis of comparison in the upcoming quarterly report from hearing aid manufacturer Demant, according to Jyske Bank.

Photo: Jens Dresling

No big surprises are in store when Demant takes stock of its performance in the first three months of the year, says Jyske Bank, a Danish bank.

As something new, Demant will also report figures for revenue and growth. This was not the case before, when the company only verbally announced results from the first and third quarters of a year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs